Assessment of DBS technology for the detection of therapeutic antibodies.

Prince PJ, Matsuda KC, Retter M, Scott G.
Journal   Bioanalysis. 2010 Aug;2(8):1449-60.
Analytes Measured  
Matrix Tested   Dried blood spots
Year   2010
Volume   2
Page Numbers   1449-1460
Application   Immunogenicity
BACKGROUND: Quantitating levels of therapeutic proteins in serum or plasma is critical for determining exposure levels and establishing pharmacokinetic parameters. Traditionally, whole blood is not used, mostly due to its inability to be frozen and potential issues with assay interference. To investigate the ability to reproducibly quantitate therapeutic antibodies present in dried blood spots (DBS) compared with a typical serum sample-based method, we used ELISA and electrochemiluminescence immunoassays to measure therapeutic drug levels present in DBS samples.

RESULTS: Measurements of antibody therapeutics in DBS were reproducible, yielding methods that are precise, accurate and met expected sensitivity requirements compared with plasma-based methods.

CONCLUSIONS: DBS are a viable alternative to the use of conventional serum or plasma samples for quantitative therapeutic antibody measures.

View Publications
Browse Our Products

By Analytes
By Applications
Customer Service/Orders

Scientific/Technical Support

Instrument Support

Company Headquarters